

## DAFTAR PUSTAKA

- Aviel-Ronen, S (July 2006). "K-ras mutations in non-small-cell lung carcinoma: a review". *Clinical Lung Cancer*. Cancer Information Group. **8** (1): 30–38. [doi:10.3816/CLC.2006.n.030](https://doi.org/10.3816/CLC.2006.n.030). PMID 16870043.
- Beau-Faller M, Prim N, Ruppert AM, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. *Ann Oncol*. 2014;25(1):126-131
- Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. *J Natl Cancer Inst* 2005;**97**:643–55
- Cataldo VD, Gibbson DL, Soler RP, Cardama AQ. Treatment of non small cell lung cancer with erlotinib and gefitinib. *N Eng J Med*. 2011; 364:947-55.
- Chabner, BA & Longo. DL, 2011, *Cancer Chemoterapy and Biotherapy: Principles and Practice*, 5edn., Philadelphia : Wolster Kluwer Bussiness.
- Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. *Transl Lung Cancer Res* 2015; 4(1): 36-54
- Chi A, Remick S, Tse W. EGFR inhibitor ini non-samall cell lung cancer: current evidence and future directions. *Biomark Res*. 2013;1:2
- Clement-Duchene, C, Vignai=und, JM, Stoufflet, A, et al., “Characteristics of never smoker lung cancer including environment and occupational risk factors”, *Lung Cancer*, vol. 67, no. 2, pp. 144.
- Crinò L, Weder W, van Meerbeeck J, Felip E; ESMO Guidelines Working Group. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: *ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up*. *Ann Oncol*. 2010;21(Suppl 5):v103–v115
- Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. *Clin Cancer Res*. 2010;16(1):291-303.
- Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac EL, et al. Non-small cell lung cancer version 3. *J National Compr Cancer Network*. 2018;13:515-24

- Ferrara, N, Hillan, KJ, Gerber, HP, et al., 2014, 'Discovery and development of bevacizumab, an antiVEGF antibody for treating cancer, *Nat Rev Drug Discov*, vol. 3, pp. 203-205
- Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. *Oncogene*. 2009;28(Suppl 1):S24–S31. doi: 10.1038/onc.2009.198. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- Herbst, RS (September 2008). "Lung cancer". *New England Journal of Medicine*. 359(13):1367-1380. doi:10.1056/NEJMr0802714. PMID 18815398
- Jorissen, RN, Wakler, F, Pouliot, N, Garrett, P, Ward, CW, dan Burgess, AW 2003, 'Epidermal growth factor receptor : mechanisms of activation and signalling', *Experimental Cell Research*, vol. 284, no. 1, pp. 31-53.
- Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med*. 2005;352(8):786-792.
- Kohler, J, Schuler, M, 2013, 'Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma ; a review', *Onkologie*, vol. 36, pp. 510-518
- Liebmman, C 2001. 'Regulation of MAP kinase activity by peptide receptor signaling pathway : Paradigms of multiplicity', *Cellular Signalling*, vol.13, no.11, pp. 777-85.
- Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med*. 2010;362(25):2380–2388. doi: 10.1056/NEJMoa0909530. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
- Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma. *N Eng J Med* 2009;361(10):947-57
- Naidoo J, Sima CS, Rodriguez K, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. *Cancer*. 2015;121(18):3212-3220.
- Niederst MJ, Hu H, Mulvey HE, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts

sensitivity to subsequent treatment strategies. Clin Cancer Res. 2015;21(17):3924-3933.

Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, et al. First-line single agent treatment with gefitinib in patients with advanced NSCLC: a phase II study. J Clin Oncol 2006;24(1):64-9.

Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004;3:465–72.

Reenen M, Jansen B. EQ-5D-5L users guide. [Online]. 2015 [Cited 2016 Juli 26]. Available from : [http://euroqol.org/wp-content/uploads/2016/09/EQ-5D-5L\\_UsersGuide\\_2015.pdf](http://euroqol.org/wp-content/uploads/2016/09/EQ-5D-5L_UsersGuide_2015.pdf)

Robbin, S.L., Cotran, R.S., Kumar. V., Collins, T., Pathology Basis Of Disease. 8th ed, International Edition, Saunders Elsevier, USA, 2009 : 721 – 729.

Rosai J. Ackerman's Surgical Pathology. 10th ed, Mosby-Year Book Inc, St. Louis, Missouri, 2011 : 366 – 384

Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560-562

Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and genetics of tumours of the lung, pleura, thymus and heart. WHO, International Agency for Research on Cancer (IARC), IARC Press, Lyon 2004 : 10 – 23, 35 – 44, 51 – 52.

Yamamoto et al. (2017) Final overall survival in JO22903, a phase II, open label study of first line erlotinib for Japanese patients with EGFR mutation positive non small cell lung cancer, Int J Clin Oncol DOI 10.1007/s10147-016- 1039-0)

Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35(12):1288-1296.

Yarden Y. The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37:S3-S8.

Yoshida T, Yamada K, Azuma K. Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis. *Med Oncol*. 2013;30:1-7

Yun CH, Boggon TJ, Li Y, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. *Cancer Cell*. 2007;11(3):217-227

Zhang Y, Sheng J, Kang S. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta analysis. *PLoS one*. 2014;9:1-9.